KRAS and lung cancer: This new antitumor compound, named Final-2, could not only suppress cancer cell growth by promoting apoptosis and blocking autophagy but also by inhibiting the expression of the oncogenes KRAS, c-MYC, and glucose transporters (GLUTs), such as GLUT1, GLUT3, and GLUT4, which resulted in the downregulation of glucose metabolism in the human lung cancer cells A549 [348].